Dirk Schadendorf, MD, professor, director, and chair of the clinic for dermatology at the University Hospital Essen in Germany, discusses the combination of targeted therapy and checkpoint blockade for the treatment of melanoma.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More